ArticlePharmaceutical research2002
Genetic immunization using nanoparticles engineered from microemulsion precursors.
Article in Pharmaceutical research, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Microneedle-mediated transcutaneous immunization with plasmid DNA coated on cationic PLGA nanoparticles.Journal of controlled release : official journal of the Controlled Release Society · 2012Article
- Ultrasonic synthetic technique to manufacture a pHEMA nanopolymeric-based vaccine against the H6N2 avian influenza virus: a preliminary investigation.International journal of nanomedicine · 2011Article
- Tresyl-based conjugation of protein antigen to lipid nanoparticles increases antigen immunogenicity.International journal of pharmaceutics · 2010Article
- Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells.International journal of pharmaceutics · 2010Article
- Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses.Expert review of vaccines · 2010Review
- Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles.Journal of controlled release : official journal of the Controlled Release Society · 2010Article
- Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel.International journal of pharmaceutics · 2009Article
- Understanding the adsorption mechanism of chitosan onto poly(lactide-co-glycolide) particles.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2008Article
- Preparation and characterization of nickel nanoparticles for binding to his-tag proteins and antigens.Pharmaceutical research · 2007Article
- Nanotechnology: intelligent design to treat complex disease.Pharmaceutical research · 2006Review
- DNA vaccine.Advances in genetics · 2005Review
- Preparation and characterization of novel coenzyme Q10 nanoparticles engineered from microemulsion precursors.AAPS PharmSciTech · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGenetic immunization using "naked" plasmid DNA (pDNA) has been shown to elicit broad humoral and cellular immune responses. However, more versatile and perhaps cell-targeted delivery systems are needed. To this end, a novel process to engineer cationic nanoparticles coated with pDNA for genetic immunization was explored. METHODS; Cationic nanoparticles were engineered from warm oil-in-water microemulsion precursors composed of emulsifying wax as the oil phase and cetyltrimethylammonium bromide (CTAB) as the cationic surfactant. Plasmid DNA was coated on the surface of the cationic nanoparticles to produce pDNA-coated nanoparticles. An endosomolytic lipid and/or a dendritic cell-targeting ligand (mannan) were incorporated in or deposited on the nanoparticles to enhance the in vitro cell transfection efficiency and the in vivo immune responses after subcutaneous injection to Balb/C mice. The IgG titer to expressed beta-galactosidase and the cytokine release from isolated splenocytes after stimulation were determined on 28 days.
resultsCationic nanoparticles (around 100 nm) were engineered within minutes. The pDNA-coated nanoparticles were stable at 37 degrees C over 30 min in selected biologic fluids. Transmission electron microscopy showed the nanoparticles were spherical. Plasmid DNA-coated nanoparticles. especially those with both an endosomolytic lipid and dendritic cell-targeting ligand. resulted in significant enhancement in both IgG titer (over 16-fold) and T-helper type-1 (Th1-type) cytokine release (up to 300% increase) over "naked" pDNA.
conclusionA novel method to engineer pDNA-coated nanoparticles for enhanced in vitro cell transfection and enhanced in vivo immune responses was reported.
Indexed as
Identifiers
12180545What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.